8-K: PepGen Announces Third Quarter 2024 Financial Results and Provides Clinical Program Updates

PepGen reported its Q3 2024 financial results and provided updates on its clinical programs, including expected data readouts for its DM1 and DMD trials.

Summary

• PepGen announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company reported a net loss of $21.4 million, or $(0.66) per share, compared to a net loss of $23.3 million, or $(0.98) per share, for the same period in 2023.
• Research and development expenses were $17.7 million for the quarter, down from $20.5 million in the same period last year.
• General and administrative expenses increased to $5.4 million from $4.2 million year-over-year.
• As of September 30, 2024, PepGen had $138.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.
• The company is advancing its clinical programs for Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD).
• Data from the 5 and 10 mg/kg cohorts of the FREEDOM-DM1 study in DM1 patients is expected in the first quarter of 2025.
• The study designs of the CONNECT program for DMD have been optimized based on encouraging early results.
• PepGen has strengthened its leadership team with the addition of Paul Streck as head of R&D.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a strong cash position, but also acknowledges the inherent risks and ongoing losses associated with a clinical-stage biotech company.

Positives

• The company's cash position of $138.9 million is expected to fund operations into 2026.
• Research and development expenses decreased year-over-year, indicating improved cost management.
• Net loss per share improved year-over-year, suggesting progress towards profitability.
• The company is making progress in its clinical programs for DM1 and DMD, with expected data readouts in the near future.
• The addition of Paul Streck as head of R&D is expected to strengthen the company's research and clinical development efforts.
• Study designs for the CONNECT program have been optimized based on encouraging early results.

Negatives

• The company reported a net loss of $21.4 million for the quarter.
• General and administrative expenses increased year-over-year.
• The company is still in the clinical stage and not yet generating revenue.

Risks

• There are risks related to delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates.
• The company faces risks related to patient enrollment in clinical trials.
• The interpretation of clinical and preclinical study results may be incorrect.
• Product candidates may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• There are risks of adverse outcomes from regulatory interactions, including delays in regulatory review or clearance to proceed.
• Unexpected increases in expenses could adversely impact financial resources and cash runway.
• The company is dependent on third parties for some or all aspects of product manufacturing, research, and testing.

Future Outlook

The company expects to report data from the FREEDOM-DM1 study in Q1 2025 and from the CONNECT1 study before year-end 2025. They also anticipate initiating dosing in the FREEDOM2 study by year-end and opening the CONNECT2 trial in the US by year-end, subject to regulatory clearance. The company's cash is expected to fund operations into 2026.

Management Comments

• James McArthur, PhD, President and CEO of PepGen, stated that they are pleased with the progress made across their pipeline and organization during the third quarter.
• James McArthur also noted that Paul Streck has already made a positive impact on the organization and clinical development strategy.
• Paul Streck, MD, MBA, Head of R&D, mentioned that they are encouraged by the emerging data from both the 5 and 10 mg/kg cohorts of the DM1 program.
• Dr. McArthur stated that they leveraged the encouraging 5 mg/kg results from the CONNECT1-EDO51 study in DMD to further optimize the study designs of both CONNECT1 and CONNECT2-EDO51.

Industry Context

PepGen is operating in the competitive biotechnology sector, focusing on oligonucleotide therapies for neuromuscular and neurological diseases. The company's progress in clinical trials and its focus on rare diseases aligns with current industry trends in developing targeted therapies for unmet medical needs. The company's focus on DMD and DM1 places it in competition with other companies developing therapies for these conditions.

Comparison to Industry Standards

• PepGen's cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• The company's focus on oligonucleotide therapies is in line with a growing trend in the industry, with companies like Sarepta Therapeutics and BioMarin also developing similar therapies.
• The reported net loss is typical for a clinical-stage biotech company, as significant revenue generation is not expected until products are approved and commercialized.
• The company's R&D spending is consistent with other companies in the space, reflecting the high cost of drug development.
• The clinical trial design adjustments based on early data are a common practice in the industry, aimed at optimizing trial outcomes.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the company's strong cash position.
• Employees may be positively impacted by the company's growth and the addition of experienced leadership.
• Patients with DM1 and DMD may benefit from the development of new therapies.
• The company's suppliers and partners may see continued business opportunities.

Next Steps

• PepGen will report safety, splicing correction and functional outcome measures from both the 5 mg/kg and 10 mg/kg dose cohorts of the FREEDOM-DM1 study by the end of the first quarter of 2025.
• The company expects to report results from the 15 mg/kg cohort of the FREEDOM-DM1 study in the second half of 2025.
• PepGen plans to initiate dosing in the FREEDOM2 study by year-end.
• The company expects to report data from the expanded CONNECT1 10 mg/kg cohort before year-end 2025.
• PepGen continues to engage with regulators in the European Union and expects to open the CONNECT2 clinical trial in the United States by year-end, subject to regulatory clearance.

Key Dates

Keywords

PepGen, Oligonucleotide Therapies, Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, Clinical Trials, PGN-EDODM1, PGN-EDO51, Biotechnology, Neuromuscular Diseases, Financial Results